InvestorsHub Logo
Followers 13
Posts 697
Boards Moderated 0
Alias Born 01/12/2013

Re: None

Thursday, 10/03/2013 7:15:00 AM

Thursday, October 03, 2013 7:15:00 AM

Post# of 130503
After positive Phase IIb results in the treatment of levodopa (L-dopa) induced dyskinesia in Parkinson’s disease (DPD), Santhera is now intending to build a partnership for further
development and commercialization of Fipamezole.

A future licensee:
?? will develop and commercialize the product
?? will have the the right to use all data generated by Santhera for development and commercialization
?? may license worldwide rights, but territory of interest to be negotiated

Fipamezole for treatment of levodopa (L-dopa) induced dyskinesia in Parkinson’s disease (DPD) 700+ mio USD peak sales first-in-class opportunity for US + EU ready to enter phase III.